SUFU
SUFU encodes a component of the Sonic hedgehog (SHH; MIM 600725)/Patched (PTCH; MIM 601309) signaling pathway. Mutations in genes encoding components of this pathway are deleterious for normal development and are associated with cancer-predisposing syndromes (e.g., HPE3, MIM 142945; BCNS, MIM 109400; and GCPS, MIM 175700).[supplied by OMIM
Full Name
suppressor of fused homolog (Drosophila)
Function
Negative regulator in the hedgehog/smoothened signaling pathway (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:12068298, PubMed:12975309, PubMed:27234298, PubMed:15367681, PubMed:22365972, PubMed:24217340, PubMed:24311597, PubMed:28965847).
Down-regulates GLI1-mediated transactivation of target genes (PubMed:15367681, PubMed:24217340, PubMed:24311597).
Down-regulates GLI2-mediated transactivation of target genes (PubMed:24311597, PubMed:24217340).
Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340).
Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340).
Negative regulator of beta-catenin signaling (By similarity).
Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL) (PubMed:24311597, PubMed:28965847).
GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state (PubMed:24311597, PubMed:28965847).
Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R (PubMed:24311597, PubMed:28965847).
When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A) (PubMed:24311597, PubMed:28965847).
Required for normal embryonic development (By similarity).
Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity).
Down-regulates GLI1-mediated transactivation of target genes (PubMed:15367681, PubMed:24217340, PubMed:24311597).
Down-regulates GLI2-mediated transactivation of target genes (PubMed:24311597, PubMed:24217340).
Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340).
Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340).
Negative regulator of beta-catenin signaling (By similarity).
Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL) (PubMed:24311597, PubMed:28965847).
GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state (PubMed:24311597, PubMed:28965847).
Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R (PubMed:24311597, PubMed:28965847).
When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A) (PubMed:24311597, PubMed:28965847).
Required for normal embryonic development (By similarity).
Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity).
Biological Process
Biological Process aorta developmentIEA:Ensembl
Biological Process coronary vasculature developmentIEA:Ensembl
Biological Process cytoplasmic sequestering of transcription factorManual Assertion Based On ExperimentIBA:GO_Central
Biological Process heart loopingIEA:Ensembl
Biological Process negative regulation of DNA-binding transcription factor activityManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of hh target transcription factor activityManual Assertion Based On ExperimentIDA:ComplexPortal
Biological Process negative regulation of osteoblast differentiationManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of protein import into nucleusManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of smoothened signaling pathwayManual Assertion Based On ExperimentIMP:UniProtKB
Biological Process negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterningIEA:Ensembl
Biological Process negative regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:MGI
Biological Process negative regulation of ubiquitin-dependent protein catabolic processIEA:Ensembl
Biological Process neural tube closureIEA:Ensembl
Biological Process regulation of DNA-templated transcriptionManual Assertion Based On ExperimentTAS:UniProtKB
Biological Process signal transductionManual Assertion Based On ExperimentTAS:ProtInc
Biological Process skin developmentIEA:Ensembl
Biological Process smoothened signaling pathway involved in dorsal/ventral neural tube patterningIEA:Ensembl
Biological Process smoothened signaling pathway involved in spinal cord motor neuron cell fate specificationIEA:Ensembl
Biological Process smoothened signaling pathway involved in ventral spinal cord interneuron specificationIEA:Ensembl
Biological Process ventricular septum developmentIEA:Ensembl
Biological Process coronary vasculature developmentIEA:Ensembl
Biological Process cytoplasmic sequestering of transcription factorManual Assertion Based On ExperimentIBA:GO_Central
Biological Process heart loopingIEA:Ensembl
Biological Process negative regulation of DNA-binding transcription factor activityManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of hh target transcription factor activityManual Assertion Based On ExperimentIDA:ComplexPortal
Biological Process negative regulation of osteoblast differentiationManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of protein import into nucleusManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of smoothened signaling pathwayManual Assertion Based On ExperimentIMP:UniProtKB
Biological Process negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterningIEA:Ensembl
Biological Process negative regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:MGI
Biological Process negative regulation of ubiquitin-dependent protein catabolic processIEA:Ensembl
Biological Process neural tube closureIEA:Ensembl
Biological Process regulation of DNA-templated transcriptionManual Assertion Based On ExperimentTAS:UniProtKB
Biological Process signal transductionManual Assertion Based On ExperimentTAS:ProtInc
Biological Process skin developmentIEA:Ensembl
Biological Process smoothened signaling pathway involved in dorsal/ventral neural tube patterningIEA:Ensembl
Biological Process smoothened signaling pathway involved in spinal cord motor neuron cell fate specificationIEA:Ensembl
Biological Process smoothened signaling pathway involved in ventral spinal cord interneuron specificationIEA:Ensembl
Biological Process ventricular septum developmentIEA:Ensembl
Cellular Location
Cytoplasm
Nucleus
Nucleus
Involvement in disease
Medulloblastoma (MDB):
Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.
Joubert syndrome 32 (JBTS32):
A form of Joubert syndrome, a disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis, and polydactyly. JBTS32 inheritance is autosomal recessive.
Basal cell nevus syndrome (BCNS):
An autosomal dominant disease characterized by nevoid basal cell carcinomas and developmental abnormalities such as rib and craniofacial alterations, polydactyly, syndactyly, and spina bifida. In addition, the patients suffer from a multitude of tumors like basal cell carcinomas, fibromas of the ovaries and heart, cysts of the skin, jaws and mesentery, as well as medulloblastomas and meningiomas.
Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.
Joubert syndrome 32 (JBTS32):
A form of Joubert syndrome, a disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis, and polydactyly. JBTS32 inheritance is autosomal recessive.
Basal cell nevus syndrome (BCNS):
An autosomal dominant disease characterized by nevoid basal cell carcinomas and developmental abnormalities such as rib and craniofacial alterations, polydactyly, syndactyly, and spina bifida. In addition, the patients suffer from a multitude of tumors like basal cell carcinomas, fibromas of the ovaries and heart, cysts of the skin, jaws and mesentery, as well as medulloblastomas and meningiomas.
PTM
Polyubiquitinated at Lys-257 by the SCF(FBXL17) complex, leading to its subsequent degradation and allowing the release of GLI1 for proper hedgehog/smoothened signal transduction (PubMed:27234298).
Ubiquitination is impaired by phosphorylation at Ser-342, Ser-346, Ser-352 and Thr-353 (PubMed:27234298).
Phosphorylation at Ser-342, Ser-346, Ser-352 and Thr-353 prevents ubiquitination by the SCF(FBXL17) complex.
Ubiquitination is impaired by phosphorylation at Ser-342, Ser-346, Ser-352 and Thr-353 (PubMed:27234298).
Phosphorylation at Ser-342, Ser-346, Ser-352 and Thr-353 prevents ubiquitination by the SCF(FBXL17) complex.
View more
Anti-SUFU antibodies
+ Filters
Loading...
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Human, Mouse, Monkey
Clone: C81H7
Application*: WB, IP
Target: SUFU
Host: Mouse
Antibody Isotype: IgG2a, κ
Specificity: Human
Clone: 1B2
Application*: SE, E
Target: SUFU
Host: Mouse
Antibody Isotype: IgG2a, κ
Specificity: Human
Clone: CBXS-2695
Application*: E
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Mouse, Rat, Human
Clone: CBXS-1178
Application*: WB, IP, P, IC, F, IF
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Human, Mouse, Rat, Monkey
Clone: CBXS-0838
Application*: WB
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Mouse, Rat, Human
Clone: CBXS-6134
Application*: IP, WB
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Human, Mouse
Clone: CBXS-5554
Application*: IP, WB
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Human, Mouse, Monkey
Clone: CBXS-6006
Application*: WB, IP
Target: SUFU
Host: Rabbit
Antibody Isotype: IgG
Specificity: Human, Mouse, Rat, Monkey
Clone: CBXS-6000
Application*: WB
More Infomation
Hot products 
-
Mouse Anti-COL12A1 Recombinant Antibody (CBYY-C3117) (CBMAB-C4560-YY)
-
Mouse Anti-DMPK Recombinant Antibody (CBYCD-324) (CBMAB-D1200-YC)
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Mouse Anti-ADGRE5 Recombinant Antibody (V2-360335) (CBMAB-C2088-CQ)
-
Mouse Anti-BBS2 Recombinant Antibody (CBYY-0253) (CBMAB-0254-YY)
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
-
Mouse Anti-ACVR1C Recombinant Antibody (V2-179685) (CBMAB-A1041-YC)
-
Mouse Anti-ABL2 Recombinant Antibody (V2-179121) (CBMAB-A0364-YC)
-
Mouse Anti-BLK Recombinant Antibody (CBYY-0618) (CBMAB-0621-YY)
-
Mouse Anti-ALOX5 Recombinant Antibody (33) (CBMAB-1890CQ)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7719) (CBMAB-1898CQ)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Rat Anti-CD34 Recombinant Antibody (MEC 14.7) (CBMAB-C10196-LY)
-
Rat Anti-AChR Recombinant Antibody (V2-12500) (CBMAB-0990-CN)
-
Mouse Anti-APCS Recombinant Antibody (CBYC-A663) (CBMAB-A3054-YC)
-
Mouse Anti-AGK Recombinant Antibody (V2-258056) (CBMAB-M0989-FY)
-
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CBMAB-A4345-YC)
-
Mouse Anti-AK4 Recombinant Antibody (V2-180419) (CBMAB-A1891-YC)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry




